Shilpa Medicare signs long-term CDMO manufacturing deal with NXI Therapeutics
The partnership covers the entire product lifecycle from early-stage development through commercialization
The partnership covers the entire product lifecycle from early-stage development through commercialization
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Subscribe To Our Newsletter & Stay Updated